MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-33-0047082
Raptim Research Private Limited - life sciences in Navi Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹146.15 Cr
▼ 4% YoY
Net loss · FY 2025
₹6.4 Cr
Net margin -4.4%
EBITDA · FY 2025
₹3.63 Cr
EBITDA margin 2.5%
Authorised capital
₹2.5 Cr
Registered with MCA
Paid-up capital
₹70 Lakh
Issued & subscribed
Open charges
₹18.04 Cr
Satisfied ₹18.11 Cr
Company age
24 yrs
Est. 2002
Directors on board
3
As per MCA filings
About Raptim Research Private Limited
Data last updated:
Raptim Research Private Limited is a private limited company based in Navi Mumbai, Maharashtra, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 17 June 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U73100MH2002PTC136230. Its GSTIN is 27AACCR2178P1ZT (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹2.5 Cr and a paid-up capital of ₹70 Lakh. It was formerly known as Raptim Research Limited. It is led by directors including Rajen Dhirubhai Shah (Whole-Time Director) and Viraj Dhirubhai Shah.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A – 242 Ttc Industrial Area Mahape MIDC Mahape, Navi Mumbai, Maharashtra, India – 400710.
As per the financials filed for FY 2025, the company reported a revenue of ₹146.15 Cr, a decline of 4% compared to the previous year. For the same year it recorded a net loss of ₹6.4 Cr (net margin -4.4%) and EBITDA of ₹3.63 Cr (EBITDA margin 2.5%). Revenue has grown at a compounded annual rate (CAGR) of 4% over three years and 12% over five years.
The company is associated with 1 brand: Raptim Research. As per MCA filings, the company has open charges of ₹18.04 Cr and satisfied charges of ₹18.11 Cr on record.
Raptim Research Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0047082). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website raptimresearch.com.
Company details
CIN U73100MH2002PTC136230
Registration Number 136230
Incorporation Date 17 June 2002
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-33-0047082
Key People
Rajen Dhirubhai Shah Whole-Time Director Viraj Dhirubhai Shah Director Meghana Rajen Shah Director Recognitions & Rankings of Raptim Research
Contact details
Raptim Research Private Limited's registered office is in Navi Mumbai, Maharashtra. Its website is raptimresearch.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA – 242 Ttc Industrial Area Mahape MIDC Mahape, Navi Mumbai, Maharashtra, India – 400710
- IndustryLife Sciences, Biotechnology
To see the full contact details of Raptim Research Private Limited, buy the company report.
Comprehensive company report
Raptim Research Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Raptim Research operates one associated brand: Raptim Research. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Delivers clinical trials, BA/BE studies, and in-vitro testing for pharmaceutical companies worldwide. | raptimresearch.com |
Business activity
The main business activity of Raptim Research is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Raptim Research Private Limited, buy the company report.
Financials of Raptim Research Private Limited
FY 2025 filings availableRaptim Research Private Limited reported revenue of ₹146.15 Cr (down 4% YoY) for FY 2025.
Revenue · FY 2025
₹146.15 Cr ▼ 4%
Net loss · FY 2025
₹6.4 Cr margin -4.4%
EBITDA · FY 2025
₹3.63 Cr margin 2.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 4%
3 years · compounded
▼ 4%
5 years · compounded
▲ 12%
EBITDA CAGR growth
1 year
▼ 70%
3 years · compounded
▼ 60%
5 years · compounded
▼ 27%
Revenue fell 4% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 12%. EBITDA fell 70% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.63 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹6.4 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 2.5% | ||||
| Net Profit Margin | -4.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Raptim Research Private Limited, buy the company report.
Board of directors of Raptim Research Private Limited
Raptim Research has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajen Dhirubhai Shah Also directs: Citus Research LLP, Nova Chemdrugs Private Limited | Whole-Time Director | 29 Jun 2004 | 22 Years 3 Months | Current |
| Viraj Dhirubhai Shah Also directs: Citus Research LLP, Nova Chemdrugs Private Limited | Director | 10 Apr 2009 | 17 Years 6 Months | Current |
| Meghana Rajen Shah Also directs: Nova Chemdrugs Private Limited | Director | 19 Feb 2024 | 2 Years 8 Months | Current |
Peer comparison
Raptim Research Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Aurigene Oncology Limited | ₹171.93 Cr (FY 2025) | -57.0% | Bangalore, Karnataka, India | |||
| Amgen Technology Private Limited | ₹166.38 Cr (FY 2025) | 601.0% | Mumbai, Maharashtra, India | |||
| Jamp India Pharmaceuticals Private Limited | ₹155.09 Cr (FY 2025) | 19.0% | Ahmedabad, Gujarat, India | |||
| Raptim Research Private Limitedthis company | ₹146.15 Cr (FY 2025) | -₹6.4 Cr | -4.4% | -4.0% | Navi Mumbai, Maharashtra, India | |
| Synzeal Research Private Limited | ₹144.48 Cr (FY 2025) | 19.0% | Bavla, Gujarat, India | |||
| Amneal Oncology Private Limited | ₹144.26 Cr (FY 2025) | 19.0% | Ahmedabad, Gujarat, India | |||
| Navitas Life Sciences Private Limited | ₹125.66 Cr (FY 2025) | -4.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Raptim Research Private Limited, buy the company report.
Auditor
Raptim Research Private Limited is audited by DESAI SAKSENA & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DESAI SAKSENA & ASSOCIATES | FY 2023 | 102358W |
Shareholding
The shareholding of Raptim Research Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Raptim Research Private Limited, buy the company report.
Charges & borrowings
Open charges
₹18.04 Cr
Satisfied charges
₹18.11 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Mar 2024 | 100894241 | Others | ₹6.07 Cr | Open | |
| 16 Jan 2023 | 100668717 | Others | ₹3 Cr | Open | |
| 24 May 2021 | 100461420 | Others | ₹82 Lakh | Open | |
| 27 Feb 2021 | 100427134 | Tata Capital Financial Services Limited | ₹5.65 Cr | Open | |
| 09 Sep 2015 | 10614821 | Others | ₹2.5 Cr | Open |
To see the full charge records of Raptim Research Private Limited, buy the company report.
Total charge records: 12 View all charges
Legal cases
No court or tribunal cases involving Raptim Research Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Raptim Research Private Limited has 15 MSME Form 1 returns on record between 2018 and 2024, listing 195 overdue payments to 86 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 86)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Simson Pharma Limited | |||
| an individual supplier | |||
| Lifepoint Research LLP | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Raptim Research Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Raptim Research has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCR2178P1ZT | Maharashtra | Active | 01 Jul 2017 |
| 24AACCR2178P1ZZ | Gujarat | Active | 12 Oct 2017 |
To see the full GST registrations and return filing status of Raptim Research Private Limited, buy the company report.
Recent activity
Raptim Research Private Limited has 11 board changes on record since 2002: 7 appointments and 4 cessations. The latest: Yellavajjhula Kamalakara Rao ceased to be Director on 30 Apr 2024.
AGM
Raptim Research Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Raptim Research Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
A charge registered on 06 Sep 2018 via Charge ID 100206296 with Tata Capital Financial Services Limited was fully satisfied on 13 Nov 2024.
Charges
A charge registered on 24 Sep 2018 via Charge ID 100216014 with Others was fully satisfied on 24 Sep 2024.
Charges
A charge with Others of Rs. 6.07 Cr registered on 26 Mar 2024 with Charge ID 100894241 was modified on 23 Aug 2024.
Charges
A charge with Others of Rs. 0.82 Cr registered on 24 May 2021 with Charge ID 100461420 was modified on 23 Aug 2024.
Charges
A charge with Others of Rs. 2.50 Cr registered on 09 Sep 2015 with Charge ID 10614821 was modified on 23 Aug 2024.
Ceased
Yellavajjhula Kamalakara Rao ceased to be Director.
Charges
A charge with Others amounted to Rs. 6.07 Cr with Charge ID 100894241 was registered on 26 Mar 2024.
Appointed
Meghana Rajen Shah was appointed as Director.
Charges
A charge registered on 11 Jun 2018 via Charge ID 100187717 with Others was fully satisfied on 26 Jul 2023.
Charges
A charge registered on 15 Nov 2016 via Charge ID 100066670 with Others was fully satisfied on 02 Mar 2023.
26 earlier events are in the company report.
Frequently asked questions
Raptim Research is an active private limited company based in Navi Mumbai, Maharashtra, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 17 June 2002 (24+ years old) and is registered under CIN U73100MH2002PTC136230.
Raptim Research has 3 current directors:
- Rajen Dhirubhai Shah - Whole-Time Director
- Viraj Dhirubhai Shah - Director
- Meghana Rajen Shah - Director
The latest financial statements of Raptim Research on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Raptim Research is 27AACCR2178P1ZT, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 24AACCR2178P1ZZ (Gujarat).
The CIN (Corporate Identification Number) of Raptim Research is U73100MH2002PTC136230. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Raptim Research was incorporated on 17 June 2002, making it 24+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Raptim Research by revenue are Aurigene Oncology Limited, Amgen Technology Private Limited, Jamp India Pharmaceuticals Private Limited, Synzeal Research Private Limited, Amneal Oncology Private Limited and 1 more, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).
Yellavajjhula Kamalakara Rao ceased to be Director on 30 Apr 2024. Meghana Rajen Shah was appointed as Director on 19 Feb 2024. Manoj Dhirajlal Shah ceased to be Director on 02 May 2018. Raptim Research has 11 board changes on record in total.
Yes, Raptim Research is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-33-0047082).
Raptim Research has 15 MSME Form 1 returns on record between 2018 and 2024, listing 195 overdue payments to 86 micro and small suppliers. The latest return was filed on 26 Apr 2024.
Raptim Research can be reached through the website raptimresearch.com. Its registered office is in Navi Mumbai, Maharashtra, India.
The registered office of Raptim Research is at A – 242 Ttc Industrial Area Mahape MIDC Mahape, Navi Mumbai, Maharashtra, India – 400710.